The role of chemokine and chemokine receptor gene variants on the susceptibility and clinicopathological characteristics of bladder cancer

Gene

Volumn 511, Issue 1, 2012, Pages 7-11

  Kucukgergin, Canan ^a   Isman, Ferruh K ^b   Dasdemir, Selcuk ^c   Cakmakoglu, Bedia ^c   Sanli, Oner ^a   Gokkusu, Cahide ^a   Seckin, Sule ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b Clinical Biochemistry Laboratory   (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

Author keywords

CCR2 gene polymorphism; CCR5 32; CCR5 59029; CXCR4; MCP 1; SDF 1

Indexed keywords

CHEMOKINE RECEPTOR CCR2A; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; MONOCYTE CHEMOTACTIC PROTEIN 1; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER RISK; CANCER STAGING; CANCER SUSCEPTIBILITY; CCR5 GENE; CLINICAL FEATURE; CONTROLLED STUDY; CXCR4 GENE; DNA POLYMORPHISM; FEMALE; GENE; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MCP1 GENE; PRIORITY JOURNAL; RECEPTOR GENE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SDF1 GENE; TURKEY (REPUBLIC);

AGED; BASE SEQUENCE; CASE-CONTROL STUDIES; CHEMOKINE CCL2; CHEMOKINE CXCL12; CHEMOKINES; DNA PRIMERS; EPISTASIS, GENETIC; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; MALE; MIDDLE AGED; RECEPTORS, CCR2; RECEPTORS, CCR5; RECEPTORS, CHEMOKINE; RECEPTORS, CXCR4; RISK FACTORS; TURKEY; URINARY BLADDER NEOPLASMS;

EID: 84867633653     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2012.09.011     Document Type: Article

References (43)

1. Abdi R.C., et al. Chemokine receptor polymorphism and risk of acute rejection in human renal transplantation. J. Am. Soc. Nephrol. 2002, 13:754-758.
2. Ahirwar D.K., et al. IL-8-251 TOA polymorphism is associated with bladder cancer susceptibility and outcome after BCG immunotherapy in a Northern Indian cohort. Arch. Med. Res. 2010, 41:97-103.
3. Balkwill F. Cancer and the chemokine network. Nat. Rev. Cancer 2004, 4:540-550.
4. Bleul C.C., et al. A highly efficaciuous lymphocyte chemoattractant, stromal cell derived factor1 (SDF-1). J. Exp. Med. 1996, 184:1101-1109.
5. Chen M.K., et al. CCR2-64I gene polymorphism increase susceptibility to oral cancer. Oral Oncol. 2011, 47:577-582.
6. Coelho A., et al. Protective role of the polymorphism CCR2-64I in the progression from squamous intraepithelial lesions to invasive cervical carcinoma. Gynecol. Oncol. 2005, 96:760-764.
7. Coelho A., et al. CXCL12-3' A polymorphism and lung cancer metastases protection: new perspectives in immunotherapy? Cancer Immunol. Immunother. 2006, 55:639-643.
8. Craig M.J., Loberg R.D. CCL2 (monocyte chemoattractant protein-1) in cancer bone metastases. Cancer Metastasis Rev. 2006, 25:611-619.
9. Deshmane S.L., et al. Monocyte chemoattractant protein-1 (MCP-1): an overview. J. Interferon Cytokine Res. 2009, 29:313-326.
10. Dranoff G., et al. Cytokines in cancer pathogenesis and cancer therapy. Nat. Rev. Cancer 2004, 4:11-22.
11. Eisenhardt A., et al. Expression analysis and potential functional role of the CXCR4 chemokine receptor in bladder cancer. Eur. Urol. 2005, 47:111-117.
12. Engl T., et al. CXCR4 chemokine receptor mediates prostate tumor cell adhesion through alpha5 and beta3 integrins. Neoplasia 2006, 8:290-301.
13. Franekova M., et al. Gene polymorphisms in bladder cancer. Urol. Oncol. 2008, 26:1-8.
14. Groah S.L., et al. Excess risk of bladder cancer in spinal cord injury: evidence for an association between indwelling catheter use and bladder cancer. Arch. Phys. Med. Rehabil. 2002, 83:346-351.
15. Hirata H., et al. CXCL12 G801A polymorphism is a risk factor for sporadic prostate cancer susceptibility. Clin. Cancer Res. 2007, 13:5056-5062.
16. Homey B., et al. Chemokines: agents for the immunotherapy of cancer?. Nat. Rev. Immunol. 2002, 2:175-184.
17. Huang Y., et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat. Med. 1996, 2:1240-1243.
18. Jacobs B.L., et al. Bladder cancer in 2010: how far have we come?. C.A. Cancer J. Clin. 2010, 60:244.
19. Kucukgergin C., et al. Association of polymorphisms in MCP-1, CCR2, and CCR5 genes with the risk and clinicopathological characteristics of prostate cancer. DNA Cell Biol. 2012, 31:1418-1424.
20. Lavergne E., et al. Intratumoral CC chemokine ligand 5 overexpression delays tumor growth and increases tumor cell infiltration. J. Immunol. 2004, 173:3755-3762.
21. Lee Y.L., et al. Association of genetic polymorphisms of CXCL12/SDF1 gene and its receptor, CXCR4, to the susceptibility and prognosis of non-small cell lung cancer. Lung Cancer 2011, 73:147-152.
22. Mantovani A., et al. Cancer-related inflammation. Nature 2008, 454:436-444.
23. McDermott D.H., et al. CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS). Lancet 1998, 352:866-870.
24. Narter K.F., et al. CCR2-64I is a risk factor for development of bladder cancer. Genet. Mol. Res. 2010, 9:685-692.
25. Petersen D.C., et al. Risk for HIV-1 infection associated with a common CXCL12 (SDF1) polymorphism and CXCR4 variation in an African population. J. Acquir. Immune Defic. Syndr. 2005, 40:521-526.
26. Rollins B.J. Chemokines. Blood 1997, 90:909-928.
27. Rovin B.H., et al. A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem. Biophys. Res. Commun. 1999, 259:344-348.
28. Shieh B., et al. Influence of nucleotide polymorphisms in the CCR2 gene and the CCR5 promoter on the expression of cell surface CCR5 and CXCR4. Int. Immunol. 2000, 12:1311-1318.
29. Smith M.W., et al. CCR2 chemokine receptor and AIDS progression. Nat. Med. 1997, 3:1052-1053.
30. Soriano A., et al. Plasma stromal cell-derived factor (SDF)-1 levels, SDF1-3'A genotype, and expression of CXCR4 on T lymphocytes: their impact on resistance to human immunodeficiency virus type 1 infection and its progression. J. Infect. Dis. 2002, 186:922-931.
31. Srivastava A., et al. CCR5 Delta32 polymorphism: associated with gallbladder cancer susceptibility. Scand. J. Immunol. 2008, 67:516-522.
32. Sutton A., et al. Stromal cell-derived factor-1/chemokine (C-X-C motif) ligand 12 stimulates human hepatoma cell growth, migration, and invasion. Mol. Cancer Res. 2007, 5:21-33.
33. Szalai C., et al. Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp (a) and MCP-1-2518G/G genotype in CAD patients. Atherosclerosis 2001, 158:233-239.
34. Teng Y.H., et al. Contribution of genetic polymorphisms of stromal cell-derived factor-1 and its receptor, CXCR4, to the susceptibility and clinicopathologic development of oral cancer. Head Neck 2009, 31:1282-1288.
35. Vaday G.G., et al. Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate 2006, 1:124-134.
36. Vázquez-Lavista L.G., et al. Genetic association of monocyte chemoattractant protein 1 (MCP-1)-2518 polymorphism in Mexican patients with transitional cell carcinoma of the bladder. Urology 2009, 74:414-418.
37. Vicari A.P., Caux C. Chemokines in cancer. Cytokine Growth Factor Rev. 2002, 13:143-145.
38. Weng C.J., et al. Effect of CC chemokine ligand 5 and CC chemokine receptor 5 genes polymorphisms on the risk and clinicopathological development of oral cancer. Oral Oncol. 2010, 46:767-772.
39. Winkler C., et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. Science 1998, 279:389-393.
40. Yeh C.B., et al. Genetic polymorphism of CCR2-64I increased the susceptibility of hepatocellular carcinoma. J. Surg. Oncol. 2010, 102:264-270.
41. Yoshie O., et al. Chemokines in immunity. Adv. Immunol. 2001, 78:57-110.
42. Zafiropoulos A., et al. Significant involvement of CCR2-64I and CXCL12-3a in the development of sporadic breast cancer. J. Med. Genet. 2004, 41:59.
43. Zhang J., et al. Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth. J. Natl. Cancer Inst. 2010, 102:522-528.